USTR Says Stance On Drug Patents 'Flexible' In TPP Talks

Law360, New York (November 27, 2013, 3:17 PM EST) -- The U.S. Trade Representative's office said Wednesday it will seek a “flexible” approach to pharmaceutical intellectual property provisions in the Trans-Pacific Partnership, attempting to allow access to lifesaving medicine while also retaining incentives for new drugs to be developed.

In a blog post, the USTR's office provided details on its negotiating approach across several of the intellectual property provisions that are likely to be included in the TPP, a proposed trade agreement between the U.S. and 11 other Pacific Rim countries. The office said, in general,...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.